Robot-assisted surgery of renal cell carcinoma in comorbid and frail patients

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

BACKGROUND: Renal cell carcinoma is predominantly observed in elderly patients. Many of them have multiple comorbidities, which can limit the feasibility of surgical treatment. The search for an optimal approach of radical treatment for comorbid and frail patients remains a current challenge.

AIM: To evaluate the perioperative outcomes of robot-assisted partial nephrectomy and radical nephrectomy in comorbid and frail patients with renal cell carcinoma.

MATERIALS AND METHODS: At the Almazov National Medical Research Centre we retrospectively studied the results of 118 comorbid and frail patients who underwent robot-assisted surgeries for localized renal cell carcinoma from 2012 to 2022. Mean age of men was 65.7 ± 11.4 years, and women was 61.3 ± 13.1 years. Comorbidity was assessed using the Charlson Comorbidity Index (CCI). Frailty was determined using a modified Frailty index (mFI-11). Robot-assisted partial nephrectomy and radical nephrectomy were perfomed by single experienced robotic surgeon. Perioperative functional outcomes were assessed. Renal function was evaluated based on glomerular filtration rate (GFR) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula before surgery and at 1.3, and 6 months after surgery.

RESULTS: Among 118 patients, 71 (60.2%) underwent robot-assisted partial nephrectomy, while 47 (39.8%) underwent radical nephrectomy. Postoperative complications occurred in 15 (12.7%) of patients for robot-assisted surgeries. There were no positive surgical margins. Mortality in the early postoperative period amounted to 1.7% and was associated with the development of acute cardiovascular failure.

CONCLUSIONS: Robot-assisted partial nephrectomy and radical nephrectomy for renal cell carcinoma in comorbid and “fragile” patients — the safest and optimal method of treatment, accompanied by minimal perioperative complications and mortality.

全文:

受限制的访问

作者简介

Artur Simonyan

Almazov National Medical Research Centre

编辑信件的主要联系方式.
Email: artsaimon143@gmail.com

Postgraduate student 

俄罗斯联邦, 2 Akkuratova st., Saint Petersburg, 191014

Mkrtich Mosoyan

Almazov National Medical Research Centre; Academician I.P. Pavlov First St. Petersburg State Medical University

Email: moso03@yandex.ru
ORCID iD: 0000-0003-3639-6863
SPIN 代码: 5716-9089
Scopus 作者 ID: 57208982777

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, 2 Akkuratova st., Saint Petersburg, 191014; 6–8 Lva Tolstogo st., Saint Petersburg, 197022

Gocha Shanava

Almazov National Medical Research Centre; Dzhanelidze Research Institute of Emergency Medicine

Email: dr.shanavag@mail.ru
SPIN 代码: 1706-7410

MD, Cand. Sci. (Medicine)

俄罗斯联邦, 2 Akkuratova st., Saint Petersburg, 191014; Saint Petersburg

Evgeny Gilev

Almazov National Medical Research Centre

Email: jackpafosky@gmail.com
SPIN 代码: 5773-4804

Assistant of the Department of Urology

俄罗斯联邦, 2 Akkuratova st., Saint Petersburg, 191014

Artem Vasilev

Almazov National Medical Research Centre

Email: scapaflow12@gmail.com

Assistant of the Department of Urology 

俄罗斯联邦, 2 Akkuratova st., Saint Petersburg, 191014

Dmitriy Fedorov

Almazov National Medical Research Centre

Email: tvoiurolog@gmail.com
ORCID iD: 0000-0002-6371-4620
SPIN 代码: 4359-8143

Assistant of the Department of Urology 

俄罗斯联邦, 2 Akkuratova st., Saint Petersburg, 191014

参考

  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
  2. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74–84. doi: 10.1016/j.eururo.2018.08.036
  3. Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79–87. doi: 10.14740/wjon1279
  4. Brivio P, Paladini MS, Racagni G, et al. From healthy aging to frailty: In search of the underlying mechanisms. Curr Med Chem. 2019;26(20):3685–3701. doi: 10.2174/0929867326666190717152739
  5. Kingston A, Robinson L, Booth H, et al. Projections of multi-morbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model. Age Ageing. 2018;47(3):374–380. doi: 10.1093/ageing/afx201
  6. Feinstein AR. The pre-therapeutic classification of comorbidity in chronic disease. J Chronic Dis. 1970;23(7):455–468. doi: 10.1016/0021-9681(70)90054-8
  7. Oganov RG, Denisov IN, Simanenkov VI, et al. Comorbidities in practice. Clinical guidelines. Cardiovascular Therapy and Prevention. 2017;16(6):5–56. EDN: ZVZZGR doi: 10.15829/1728-8800-2017-6-5-56
  8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8
  9. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3): M146–M156. doi: 10.1093/gerona/56.3.m146
  10. Dent E, Martin FC, Bergman H, et al. Management of frailty: opportunities, challenges, and future directions. Lancet. 2019;394(10206):1376–1386. doi: 10.1016/S0140-6736(19)31785-4
  11. Wleklik M, Uchmanowicz I, Jankowska EA, et al. Multidimensional approach to frailty. Front Psychol. 2020;11:564. doi: 10.3389/fpsyg.2020.00564
  12. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on renal cell carcinoma: The 2022 update. Eur Urol. 2022;82(4):399–410. doi: 10.1016/j.eururo.2022.03.006
  13. Shapiro DD, Wells SA, Best SL, et al. Comparing outcomes for patients with clinical T1b renal cell carcinoma treated with either percutaneous microwave ablation or surgery. Urology. 2020;135:88–94. doi: 10.1016/j.urology.2019.09.024
  14. Velanovich V, Antoine H, Swartz A, et al. Accumulating deficits model of frailty and postoperative mortality and morbidity: its application to a national database. J Surg Res. 2013;183(1):104–110. doi: 10.1016/j.jss.2013.01.021
  15. Kasiske BL, Wheeler DC. Kidney disease: Improving global outcomes — an update. Nephrol Dial Transplant. 2014;29(4):763–769. doi: 10.1093/ndt/gft441
  16. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9): 604–612. doi: 10.7326/0003-4819-150-9-200905050-00006
  17. Rosiello G, Re C, Larcher A, et al. The effect of frailty on post-operative outcomes and health care expenditures in patients treated with partial nephrectomy. Eur J Surg Oncol. 2022;48(8):1840–1847. doi: 10.1016/j.ejso.2022.01.001
  18. Rosiello G, Palumbo C, Deuker M, et al. Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. Surg Oncol. 2021;38:101588. doi: 10.1016/j.suronc.2021.101588

补充文件

附件文件
动作
1. JATS XML

版权所有 © Eco-Vector, 2024



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ №ФС77-65570 от 04 мая 2016 г.


##common.cookie##